Jennifer Guerriero
Mass General Brigham Cancer Institute
Jennifer Guerriero, PhD
Assistant Professor, Harvard Medical School
Lead Investigator, Mass General Brigham Cancer Institute
Breast Oncology Program, Harvard Cancer Consortium
Harvard Immunology Program, Harvard Medical School
Jennifer Guerriero, PhD, is a cancer immunologist and independent investigator at Mass General Brigham Cancer Institute and Harvard Medical School. She leads an internationally recognized research program supported by multiple NIH NCI R01 awards, the Cancer Research Institute (CRI), and the U.S. Department of Defense, focused on developing tumor-associated macrophage (TAM)-targeted immunotherapies for cancer. Her laboratory integrates tumor immunology, single-cell genomics, and cellular engineering to define the biology of TAMs and translate these discoveries into first-in-class therapies designed to harness the immune system to achieve durable remissions and ultimately cures for patients with cancer.
Dr. Guerriero's research has resulted in multiple patents, industry collaborations, and clinical translation efforts. Her work defining the role of macrophages in therapeutic resistance provided the scientific foundation for an investigator-initiated clinical trial evaluating PARP inhibition in combination with an anti-CSF1R antibody in patients with advanced breast cancer (NCT06488378). She is the inventor on patents covering a novel macrophage-targeted Class IIa histone deacetylase (HDAC) inhibitor and next-generation TREM2-targeted CAR-monocyte (CAR-Mo) cellular therapies that leverage macrophage biology to remodel the tumor microenvironment and improve outcomes for patients with solid tumors.
Dr. Guerriero leads translational research within the Breast Oncology Program at the Harvard Cancer Consortium. She is an internationally recognized leader in myeloid cell biology, serving on the Board of Directors and Executive Council of the Society for Immunotherapy of Cancer (SITC), the AACR Cancer Immunology Working Group Steering Committee, and is co-founder of The Myeloid Network, an international scientific forum dedicated to advancing myeloid cell biology and cancer immunotherapy.
She received her BS in Biochemistry from Northeastern University while on a Division I pole vault scholarship, a PhD in Molecular and Cellular Biology and Immunology from Stony Brook University, and completed her postdoctoral training at Dana-Farber Cancer Institute under Dr. Anthony Letai, and established her independent laboratory at Brigham and Women's Hospital in 2020.
Dr. Guerriero is the founder of KarMac Therapeutics.
Assistant Professor, Harvard Medical School
Lead Investigator, Mass General Brigham Cancer Institute
Breast Oncology Program, Harvard Cancer Consortium
Harvard Immunology Program, Harvard Medical School
Jennifer Guerriero, PhD, is a cancer immunologist and independent investigator at Mass General Brigham Cancer Institute and Harvard Medical School. She leads an internationally recognized research program supported by multiple NIH NCI R01 awards, the Cancer Research Institute (CRI), and the U.S. Department of Defense, focused on developing tumor-associated macrophage (TAM)-targeted immunotherapies for cancer. Her laboratory integrates tumor immunology, single-cell genomics, and cellular engineering to define the biology of TAMs and translate these discoveries into first-in-class therapies designed to harness the immune system to achieve durable remissions and ultimately cures for patients with cancer.
Dr. Guerriero's research has resulted in multiple patents, industry collaborations, and clinical translation efforts. Her work defining the role of macrophages in therapeutic resistance provided the scientific foundation for an investigator-initiated clinical trial evaluating PARP inhibition in combination with an anti-CSF1R antibody in patients with advanced breast cancer (NCT06488378). She is the inventor on patents covering a novel macrophage-targeted Class IIa histone deacetylase (HDAC) inhibitor and next-generation TREM2-targeted CAR-monocyte (CAR-Mo) cellular therapies that leverage macrophage biology to remodel the tumor microenvironment and improve outcomes for patients with solid tumors.
Dr. Guerriero leads translational research within the Breast Oncology Program at the Harvard Cancer Consortium. She is an internationally recognized leader in myeloid cell biology, serving on the Board of Directors and Executive Council of the Society for Immunotherapy of Cancer (SITC), the AACR Cancer Immunology Working Group Steering Committee, and is co-founder of The Myeloid Network, an international scientific forum dedicated to advancing myeloid cell biology and cancer immunotherapy.
She received her BS in Biochemistry from Northeastern University while on a Division I pole vault scholarship, a PhD in Molecular and Cellular Biology and Immunology from Stony Brook University, and completed her postdoctoral training at Dana-Farber Cancer Institute under Dr. Anthony Letai, and established her independent laboratory at Brigham and Women's Hospital in 2020.
Dr. Guerriero is the founder of KarMac Therapeutics.
